XML 41 R26.htm IDEA: XBRL DOCUMENT
v3.25.4

Restructuring Expenses | 12 Months Ended
--- | ---
Dec. 31, 2025
Restructuring and Related Activities [Abstract] |
Restructuring Expenses | Restructuring Expenses During 2023, due to challenging industry dynamics and macroeconomic conditions, the Company underwent several expense containment measures such as a reduction of its headcount across many of its functions and a reduction of its real estate footprint. During the year ended December 31, 2023, the restructuring initiatives incurred $15.5 million of employee severance costs and related expenses, net of reversals. Refer to Note 13, Lessee Leases for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities. On April 26, 2024, the Company’s management committed to the wind down of the Company’s Medimat Robotic Dispensing System (“RDS”) product line, subject to local law and statutory works council consultation requirements. During the year ended December 31, 2024, the Company incurred approximately $6.6 million of employee severance costs and other expenses related to the RDS product line wind down, net of immaterial reversals of previously recognized restructuring expenses. The Company also incurred $5.4 million of inventory write-down charges during the year ended December 31, 2024 related to the RDS product line wind down that were recorded to cost of revenues in the Company’s Consolidated Statements of Operations. Further, during the fourth quarter of 2025, the Company incurred additional charges related to the wind down of the Company’s RDS product line. During the year ended December 31, 2025, the Company incurred approximately $3.9 million of employee severance costs and other expenses in connection with this initiative. During the third quarter of 2025, the Company underwent a restructuring initiative within the EnlivenHealth business in order to gain operational efficiency and synergy, and adapt to the recent industry dynamics within the retail pharmacy space. During the year ended December 31, 2025, the Company incurred approximately $2.6 million of employee severance and other related expenses in connection with this initiative. As of December 31, 2025, the unpaid balance related to these restructuring plans was $3.9 million. The following table summarizes the total employee-related restructuring expense, net of reversals:
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
| (In thousands)
Cost of product and service revenues | $ | 4,601 |  |  | $ | 4,504 |  |  | $ | 3,089 |
Research and development | 937 |  |  | 419 |  |  | 3,829 |
Selling, general, and administrative | 967 |  |  | 230 |  |  | 8,621 |
Total restructuring expenses, net of reversals | $ | 6,505 |  |  | $ | 5,153 |  |  | $ | 15,539 |

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration